L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed ...
Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a ...
TipRanks on MSN
Incyte’s INCA33890: A Promising Step in Cancer Treatment
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a Phase 1 clinical study titled A ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody ...
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.
The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, ...
Cardiff Oncology (CRDF) is a speculative buy with potential blockbuster gains ahead of its 2026 data readout. Read here for ...
En esta primera edición del boletín The World, exploramos por qué un presidente que hizo campaña contra las “guerras extranjeras” está enviando buques de guerra a Venezuela. Por Katrin Bennhold Soy la ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback